The insurance company expects to return an extra $1.24 billion to shareholders via buybacks upon completion of the sale.

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

The company reported fiscal third-quarter adjusted earnings per share of 39 cents, compared with Wall Street’s consensus ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Vanguards VEA and VEU exchange trade funds both offer investors exposure to international markets and companies outside of ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.

The company’s shares rose as investors breathed a sigh of relief on strong sales growth and guidance, despite ongoing ...